Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited (IMMP) news covers a late-stage biotechnology company focused on Lymphocyte Activation Gene-3 (LAG-3)–related immunotherapies for cancer and autoimmune disease. The company regularly reports clinical, regulatory and corporate developments across its diversified LAG-3 portfolio, led by the MHC Class II agonist eftilagimod alfa (efti) and the LAG-3 agonist antibody IMP761.
On this page, readers can follow updates on Immutep’s major oncology programs, including the global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line non-small cell lung cancer, as well as Phase II and investigator-initiated studies in head and neck squamous cell carcinoma, soft tissue sarcoma and metastatic breast cancer. News items highlight trial milestones such as patient enrolment progress, primary endpoint readouts, translational biomarker data and presentations at international conferences like the European Society for Medical Oncology (ESMO), the World Conference on Lung Cancer and the San Antonio Breast Cancer Symposium.
For autoimmune disease, Immutep publishes updates on the Phase I program for IMP761, a first-in-class LAG-3 agonist antibody designed to silence dysregulated self-antigen-specific memory T cells. News coverage includes safety, pharmacodynamic findings and proof-of-concept data from the ongoing first-in-human study.
Investors can also track regulatory interactions, such as Fast Track designations, FDA feedback on late-stage development strategies and completion of Project Optimus requirements, alongside business developments like the strategic collaboration and exclusive licensing agreement with Dr. Reddy’s Laboratories for efti in selected global markets. Corporate news, including R&D tax incentives from French and Australian government programs and quarterly activity reports, provides additional context on funding and operational progress.
Bookmark this page to monitor Immutep’s latest announcements, clinical data disclosures and SEC Form 6-K filings that shape the outlook for IMMP and its LAG-3–focused pipeline.
Immutep announced the appointment of four new members to its Clinical Advisory Board (CAB), enhancing its strategic resources for advancing LAG-3-related immunotherapy treatments. The new members, experts in oncology and immunotherapy, will focus on late-stage development programs for the lead product, eftilagimod alpha. This move aims to strengthen Immutep's position as a leader in innovative cancer therapies, especially targeting metastatic breast and non-small cell lung carcinomas.
Immutep reported results from its Phase IIb AIPAC trial, demonstrating a statistically significant increase in immune response biomarkers such as monocyte and CD8 T cell counts in the efti treatment group compared to placebo. These biomarkers are correlated with improved overall survival (OS), as shown in an exploratory analysis identifying six patient subgroups that benefit from the treatment. Notably, five subgroups showed significant OS improvements, with ALC emerging as a potential predictor for survival.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) recently announced new interim data from the Phase II TACTI-002 trial for NSCLC patients showing an encouraging overall survival rate of 73.7% at the six-month mark.
Additionally, the company received constructive FDA feedback on the efti development program for metastatic breast cancer (MBC) and is proceeding with recruitment for Phase IIb TACTI-003. Immutep's cash balance is strong at $87.2 million as of March 31, 2022, despite an increase in R&D spending.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced that interim data from the Phase II TACTI-002 trial for non-small cell lung cancer will be presented at the ASCO 2022 Annual Meeting, taking place from June 3-7, 2022. The trial evaluates the combination of eftilagimod alpha and pembrolizumab. Additionally, TACTI-003 trial design will be showcased. The presentation includes significant new data not mentioned in the abstract, with over 40,000 attendees expected to participate in this prominent conference.
Immutep Limited (NASDAQ: IMMP) announced encouraging interim results from its Phase II TACTI-002 trial for 2nd line metastatic non-small cell lung carcinoma (NSCLC). Key findings include a Disease Control Rate (DCR) of 36.1% and a 73% overall survival rate at six months. 73.7% of patients experienced tumor shrinkage or deceleration, with 5.6% achieving durable partial responses. The treatment, combining eftilagimod alpha (efti) with pembrolizumab, continues to demonstrate safety and tolerability. More mature data is anticipated later this year.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced promising interim results from Part B of the TACTI-002 trial, focusing on 2nd line NSCLC patients. The combination of eftilagimod and pembrolizumab demonstrated a 6% overall response rate and a 36% disease control rate among 36 patients. The treatment was found to be safe and well-tolerated, with ongoing data on overall survival and tumour growth kinetics to be presented at the European Lung Cancer Congress (ELCC) 2022.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced new biomarker data from its Phase IIb AIPAC trial at the ESMO Breast Cancer Congress 2022, occurring from May 3-5, 2022, in Berlin, Germany. The trial assessed eftilagimod alpha combined with paclitaxel in 227 HER2-negative/HR positive metastatic breast cancer patients. New multivariate analysis results will be presented by Prof. Dr. Frederik Marmé on May 4, 2022. For further details, visit Immutep's website.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of patent no. 7030750 by the Japanese Patent Office for antibody molecules targeting LAG-3, crucial for cancer treatment. This divisional patent follows a previous grant in 2019, with corresponding patents in territories like Australia, China, Europe, and the U.S. The patent, co-owned with Novartis AG, will expire on March 13, 2035. LAG525, a humanized form of IMP701, is being evaluated by Novartis in clinical trials for cancer, with Immutep set to receive milestone payments and royalties upon commercialization.
Immutep Limited (NASDAQ: IMMP) announced that it received positive feedback from the FDA regarding its lead product, eftilagimod alpha (efti), for the treatment of metastatic breast cancer (MBC). The FDA supports advancing efti into a new registrational trial, AIPAC-003, which will optimize patient selection based on completed phase IIb AIPAC trial data. This follows earlier feedback from the EMA. The upcoming trial aims to solidify the best design for efti, which targets patients who are unlikely to benefit from conventional therapies.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced its participation in notable investor conferences, including the 42nd Annual Cowen Health Care Conference from March 7-9, 2022, where CEO Marc Voigt will present on March 8 at 9:10 am EST. A live webcast will be available. Additionally, Immutep will engage in a fireside chat at the Maxim Growth Conference from March 28-30, 2022, set for March 28 at 11:00 am EDT. Immutep focuses on developing LAG-3 related immunotherapies for cancer and autoimmune diseases.